Aeolus Announces Third Quarter Fiscal Year 2015 Financial Results
August 17, 2015 07:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - August 17, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Barda Exercises $3 MM in Additional Contract Funding for Development of AEOL 10150 as Treatment for Acute Radiation Syndrome
June 26, 2015 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - June 26, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Pharmateucticals to Present at LD Micro Invitational Conference
May 28, 2015 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 28, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...
Aeolus Announces Second Quarter Fiscal Year 2015 Financial Results
May 15, 2015 16:52 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 15, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused by Acute Radiation Exposure
May 04, 2015 07:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 04, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)FINDINGS REPORTED BY DR. THOMAS MACVITTIE OF THE UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE WILL BE INCLUDED...
Aeolus Files Patent Application and Completes Licensure of New Series of Compounds to Treat Infectious and Inflammatory Disease
April 15, 2015 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - April 15, 2015) - Company Intends to Develop New Compounds for Both Biodefense and Traditional Medical IndicationsTechnology Licensed From National Jewish Health
...
Aeolus Receives Notice of Allowance From Israeli Patent Office for Use of AEOL 10150 and Other Aeolus Compounds to Treat Injury From Exposure to Alkylating Agents Such as Sulfur Mustard Gas
March 31, 2015 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - March 31, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Receives Orphan Drug Designation From US FDA for AEOL 10150 for Treatment of Idiopathic Pulmonary Fibrosis
March 17, 2015 11:46 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - March 17, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Announces First Quarter Fiscal Year 2015 Financial Results
February 13, 2015 17:41 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - February 13, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats...
Aeolus Announces Response to FDA Clinical Hold and Plan for Clinical Development of AEOL 10150
January 08, 2015 08:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - January 08, 2015) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in...